ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Mortality Increase Of 5.2% Now 28% Or Less

January 30, 1976

Clearinghouse Role Broadened By Upton; Asked To Consider All Data In Risk Assessment

November 11, 1977

Funding Opportunities (8-page issue).

May 23, 2003

Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show

September 28, 2007

Carcinogenesis Testing To Stay In NCI, But Control Will Go To New Group Headed By Rall

September 15, 1978

NCI Searching for Scientists With “Fire in Belly” As Associate Director for Biological Carcinogenesis

June 19, 1987